Biochemical markers of ischemic stroke

Authors

  • Joanna Bielewicz Klinika Neurologii, Uniwersytet Medyczny w Lublinie Author
  • Jacek Kurzepa Katedra i Zakład Biochemii i Biologii Molekularnej, Uniwersytet Medyczny w Lublinie Author
  • Zbigniew Stelmasiak Klinika Neurologii, Uniwersytet Medyczny w Lublinie Author
  • Halina Bartosik-Psujek Klinika Neurologii, Uniwersytet Medyczny w Lublinie Author

Keywords:

biomarkers, ischemic stroke

Abstract

Because of limitations of currently available diagnostic methods (physical examination, brain imaging) the other valid and objective tests are needed for diagnosis and management of ischemic stroke (IS). In the past decade many studies have investigated biochemical markers of IS. The aim of that studies were mediators of pathophysiological processes or the compounds released from damaged tissue during ischemia. Identification of group of substances which can be measured in blood as a complimentary test would create a new diagnostic, therapeutic and prognostic opportunities in management of IS. Current review is focused on biochemical markers involved in numerous pathological processes that occur within ischemic brain tissue; oxidative stress, inflammation, apoptosis, excitotoxicity. In addition compounds involved in clotting, fibrinolysis, markers of blood-brain barrier damage as well as structural components of brain tissue that can be useful in the diagnosis of IS were discussed.

References

1. Whiteleey W., Tseng MC., Sandercock P. Blood Biomarkers in the Diagnosis of Ischemic Stroke. Stroke, 2008; 39: 2902-2909.

2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001; 69: 89-95.

3. Kumar K. Overview: use of biomarkers for early diagnosis of ischemic stroke. Curr. Opin. Investig. Drugs, 2005; 6: 2–4.

4. Parhan S. New biomarkers could deliver a strike at stroke. Cap. Today. 2004, Nov, www.cap.org

5. Jauch E.C. Biomarker advances in acute ischemic stroke. Cardiovascular and Neurovascular Emergencies. 2005, 57–63.

6. Laskowitz D.T., Grocott H., Hsia A., Copeland K.R. Serum markers of cerebral ischemia. J. Stroke Cerebrovasc. Dis., 1998; 7: 234-41.

7. Goldstein L.B., Simel D.L. Is this patient having a stroke? Jama, 2005; 293: 239-402.

8. Nor A.M., Ford G.A. Misdiagnosis of stroke. Expert. Rev. Neurother., 2007; 7: 989-1001.

9. Hill M.D. Diagnostic Biomarkers for Stroke: A Stroke Neurologist's Perspective. Clin. Chem., 2005; 51: 2001-2002.

10. Reynolds M.A., Kirchick H.J., Dahlen J..R, Anderberg J.M., McPherson P.H., Nakamura K.K., Laskowitz D.T., Valkirs G.E., Buechler K.F. Early biomarkers of stroke. Clin. Chem., 2003; 49: 1733-1739.

11. Lynch J.R., Blessing R., White W.D., Grocott H.P., Newman M.F., Laskowitz D.T. Novel diagnostic test for acute stroke. Stroke, 2004; 35: 57-63.

12. European Stroke Organisation. Postępowanie w udarze niedokrwiennym mózgu i przemijającym napadzie niedokrwienia mózgu. Medycyna Praktyczna, Wydanie specjalne, 2009; 1-64.

13. Castellanos M., Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc. Dis., 2007; Suppl 1: 7-15.

14. Vila N., Castillo J., Dávalos A., Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke, 2000; 31: 2325-2329.

15. Rosell A., Alvarez-Sabín J., Arenillas J.F., Rovira A., Delgado P., Fernández-Cadenas I, Penalba A., Molina C.A., Montaner J. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke, 2005; 36: 1415-1420.

16. Foerch C., Otto B., Singer O.C., Neumann-Haefelin T., Yan B., Berkefeld J., Steinmetz H., Sitzer M. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke, 2004; 35: 2160-2164.

17. Rosell A., Cuadrado E., Alvarez-Sabín J., Hernández-Guillamon M., Delgado P., Penalba A., Mendioroz M., Rovira A., Fernández-Cadenas I., Ribó M., Molina C.A., Montaner J. Caspase-3 is related to infarct growth after human ischemic stroke. Neurosci. Lett., 2008; 430: 1-6.

18. Frykholm P., Hillered L., Långström B., Persson L., Valtysson J., Enblad P. Relationship between cerebral blood flow and oxygen metabolism, and extracellular glucose and lactate concentrations during middle cerebral artery occlusion and reperfusion: a microdialysis and positron emission tomography study in nonhuman primates. J. Neurosurg., 2005; 102: 1076-1084.

19. Bruhn T., Christensen T., Diemer N.H. Uptake of glutamate is impaired in the cortical penumbra of the rat following middle cerebral artery occlusion: an in vivo microdialysis extraction study. J. Neurosci. Res., 2003; 71: 551-558.

20. Weinstein P.R., Hong S., Sharp F.R. Molecular identification of ischemic penumbra. Stroke, 2004; 35: suppl. 2666–2670.

21. Castillo J., Davalos A., Noya M. progression of ischaemic stroke and excitotoxic aminoacids. Lancet, 1997; 349: 79-83.

22. Castillo J., Rodriquez I. Biochemical changes and inflamatory response as markers for brain ischaemia : molecular markers of diagnostic utility and prognosis in human clinical practise. Cerebrovasc. Dis., 2004; 17 Suppl 1: 7-18.

23. Wunderlich M.T., Wallesch C.W., Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J. Neurol. Sci., 2004; 227: 49–53.

24. Bitsch A., Horn C., Kemmling Y., Seipelt M., Hellenbrand U., Stiefel M., Ciesielczyk B., Cepek L., Bahn E., Ratzka P., Prange H., Otto M. Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur. Neurol., 2002; 47: 45-51.

25. Montaner J., Alvarez-Sabin J., Molina C.A. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke, 2001; 32: 2762–2767.

26. Serena J., Blanco M., Castellanos M., Silva Y., Vivancos J., Moro M.A., Leira R., Lizasoain I., Castillo J., Dávalos A. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke, 2005; 36: 1921-1926.

27. Montaner J., Molina C.A., Monasterio J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation, 2003; 107: 598–603.

28. Laskowitz D.T., Kasner S.E., Saver J., Remmel K.S., Jauch E.C; BRAIN Study Group. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke, 2009; 40: 77-85.

29. Serena J., Leira R., Castillo J., Pumar J.M., Castellanos M., Dávalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke, 2001; 32: 1154-1161.

30. Castillo J., Rama R., Davalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke, 2000; 31: 852-857.

31. Castellanos M., Castillo J., García M.M., Leira R., Serena J., Chamorro A., Dávalos A. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke, 2002; 33: 982-987.

32. Laterza O.F., Modur V.R., Crimmins D.L., Olander J.V., Landt Y., Lee J.M., Ladenson J.H. Identification of novel brain biomarkers. Clin. Chem., 2006; 52: 1713-1721.

33. Barber M., Langhorne P., Rumley A., Lowe G.D., Stott D.J. D-dimer predicts elary clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke, 2006; 37: 1113-1115.

34. Feinberg W.M., Erickson L.P., Bruck D., Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke, 1996; 27: 1296-1300.

35. Jauch E.C., Laskowitz D.T. Can D-dimer levels identify patients at risk for early neurological deterioration in acute ischemic stroke. Nat. Clin. Pract. Neurol., 2006; 2: 590-591.

36. Delgado P., Alvarez-Sabín J., Abilleira S., Santamarina E., Purroy F., Arenillas J.F., Molina C.A., Fernández-Cadenas I., Rosell A., Montaner J. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology, 2006; 67: 94-98.

37. Sienkiewicz-Jarosz H., Gałecka-Wolska M., Bidziński A., Turzyńska D., Sobolewska A., Lipska B., Płaźnik A., Ryglewicz D.. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol. Neurochir. Pol. 2009; 43: 126-133.

38. Di Lazzaro V., Profice P., Pilato F., Dileone M., Florio L., Tonali P.A., Angelucci F. BDNF plasma levels in acute stroke. Neurosci. Lett., 2007; 422: 128-130.

39. Donato R. Functional roles of S100 proteins, calcium – binding proteins of the EF- hand type. Biochim. Biophy.s Acta, 1999; 1450: 191-231.

40. Santamaria-Kisiel L., Rintala-Dempsey A.C., Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem. J., 2006; 396: 201-214.

41. Zimmer D.B., Chaplin J., Baldwin A., Rast M. S100-mediated signal transduction in the nervous system and neurological diseases. Cell. Mol. Biol. (Noisy-le-grand), 2005; 51: 201-214.

42. Abraha H.D., Butterworth R.J., Bath P.M., Wassif W.S., Garthwaite J., Sherwood R.A. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann. Clin Biochem., 1997; 34: 546-550.

43. Büttner T., Weyers S., Postert T., Sprengelmeyer R., Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke, 1997; 28: 1961-1965.

44. Kaca-Oryńska M., Tomasiuk R., Friedman A. Neuronalna enolaza I białko S100B jako czynniki prognostyczne w udarze niedokrwiennym mózgu. Neurol. Neurochir. Pol., 2010; 44: 459-463.

45. Foerch C., Wunderlich M.T., Dvorak F., Humpich M., Kahles T., Goertler M., Alvarez-Sabín J., Wallesch C.W., Molina C.A., Steinmetz H., Sitzer M,. Montaner J. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke,2007; 38: 2491-2495.

46. Jauch E.C., Lindsell C., Broderick J., Fagan S.C., Tilley B.C., Levine S.R. NINDS rt-PA Stroke Study Group. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke, 2006; 37: 2508-2513.

47. Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H., Lamers K.J. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke, 2000; 31 : 2670-2677.

48. Wunderlich M..T, Wallesch C.W., Goertler M. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur. J. Neurol, 2006; 13: 1118–1123.

Downloads

Published

2012-02-07

Issue

Vol. 12 No. 4 (2011): Current Problems of Psychiatry

Section

Artykuły

License

Copyright (c) 2011 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.